Susilo Wagino MulyoThe advent of Glucagon-like peptide-1 receptor agonists (GLP-1s) has revolutionized the management of type 2 diabetes and, more recently, chronic weight management. Medications such as Ozempic, a semaglutide-based GLP-1, have…
Susilo Wagino MulyoThe emergence of Glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic, Wegovy, and Zepbound, has introduced a new paradigm in the management of chronic conditions, particularly type 2 diabetes and…
Susilo Wagino MulyoThe landscape of sleep apnea treatment is undergoing a significant evolution with the emergence of Glucagon-like Peptide-1 (GLP-1) receptor agonists, a class of medications initially developed for type 2 diabetes…
Susilo Wagino MulyoThe intersection of rapidly advancing pharmaceutical treatments for weight management and chronic conditions like sleep apnea is creating a complex and often costly landscape for patients and healthcare providers. Glucagon-like…
